

Accepted Manuscript

CORK study in CF: Sustained improvements in ultra-low dose chest CT scores post CFTR modulation with ivacaftor.

Nicola J. Ronan, MB BCh, Gisli G. Einarsson, PhD, Maria Twomey, Denver Mooney, David Mullane, MD, Muireann NiChroinin, MD, Grace O'Callaghan, PhD, Fergus Shanahan, Desmond M. Murphy, PhD, Owen J. O'Connor, Cathy A. Shortt, BSc, Michael M. Tunney, PhD, Joseph A. Eustace, MD, Michael M. Maher, MD, J Stuart Elborn, MD, Barry J. Plant, MD

PII: S0012-3692(17)32896-9

DOI: [10.1016/j.chest.2017.10.005](https://doi.org/10.1016/j.chest.2017.10.005)

Reference: CHEST 1385

To appear in: *CHEST*


Received Date: 23 July 2017

Revised Date: 16 September 2017

Accepted Date: 2 October 2017

Please cite this article as: Ronan NJ, Einarsson GG, Twomey M, Mooney D, Mullane D, NiChroinin M, O'Callaghan G, Shanahan F, Murphy DM, O'Connor OJ, Shortt CA, Tunney MM, Eustace JA, Maher MM, Elborn JS, Plant BJ, CORK study in CF: Sustained improvements in ultra-low dose chest CT scores post CFTR modulation with ivacaftor., *CHEST* (2017), doi: 10.1016/j.chest.2017.10.005.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Title: CORK study in CF: Sustained improvements in ultra-low dose chest CT scores post CFTR modulation with ivacaftor.

Running Title: CORK study

Authors: Nicola J Ronan^{1,2} MB BCh, Gisli G Einarsson³ PhD, Maria Twomey⁴, Denver Mooney³, David Mullane¹ MD, Muireann NiChroinin¹ MD, Grace O'Callaghan^{1,2} PhD, Fergus Shanahan⁵, Desmond M Murphy^{1,2} PhD, Owen J O'Connor⁴, Cathy A Shortt¹ BSc, Michael M Tunney³ PhD, Joseph A Eustace² MD, Michael M Maher⁴ MD, J Stuart Elborn^{3,6} MD, Barry J Plant^{1,2} MD

¹Cork Cystic Fibrosis Centre, Cork University Hospital, University College Cork, Ireland

²HRB Clinical Research Facility, University College Cork, Cork, Ireland

³CF & Airways Microbiology Research Group, Queen's University Belfast, Belfast, United Kingdom

⁴Department of Radiology, Cork University Hospital, University College Cork, Cork, Ireland.

⁵Department of Medicine, Cork University Hospital, Wilton, Cork, Ireland

⁶ Imperial College and Royal Brompton Hospital, London, UK

Corresponding Author: Barry J Plant, Cork Cystic Fibrosis Centre, Cork University Hospital University College Cork, Wilton, Cork. Email: b.plant@ucc.ie.

Contribution: NJR, FS, JAE, MMM and BJP contributed to study design. NJR, GGE, MT DM, DM, MC, GOC, DMM, OJOC, CAS, MMT, JAE, MMM, JSE and BJP contributed to data acquisition, analysis and interpretation. All authors contributed to drafting the work and final approval.

Word count: 2,493

Key Words: Cystic Fibrosis, ivacaftor, G551D, low-dose chest CT

Funding: We would like to acknowledge funding from the European Commission for CFMATTERS, Grant agreement 603038

IRB statement: Ethical approval was received from the clinical research ethics committee of the Cork Teaching Hospitals (CREC). ECM 4 (j) 02/07/13

Conflicts of interest: NJR, GGE, MT, DM, MNC, GOC, FS, CS, JAE report no conflicts of interest. Prof Elborn reports grants, personal fees and other from Vertex, personal fees and other from Galapagos, personal fees and other from Proteostasis, personal fees and other from ProQr, other from Flatley. Dr O'Connor and Prof Maher reports other from GE Healthcare, outside the submitted work. Prof Plant has received honoraria/speakers fees from Gilead Sciences, Novartis Pharmaceutical, Vertex Pharmaceutical, outside the submitted work. Dr. Mullane reports personal fees from Vertex pharmaceuticals, outside the submitted work. Dr. Murphy reports an APC grant from University College Cork and funding from the Wilton Respiratory Research Fund to support this research. He is the past recipient of an ERS fellowship. He has received fees for consultancy work from Novartis, Bayer, AstraZeneca, Menarini, Nycomed, Gilead, Boehringer Ingelheim, Teva, Rowex and

Download English Version:

<https://daneshyari.com/en/article/8658035>

Download Persian Version:

<https://daneshyari.com/article/8658035>

[Daneshyari.com](https://daneshyari.com)